Medirom Healthcare Technologies Inc Stock Price, News & Analysis

MEDIROM Healthcare Technologies is set to acquire a 70% stake in Japan Gene Medicine , a leader in prenatal diagnosis and genetic testing, and has an option to acquire the remaining 30%. The acquisition process started on June 30, 2024, and is subject to certain conditions, including amending subcontracting agreements and securing funding. Japan Gene Medicine operates in an underutilized market in Japan, with only 7.2% of pregnant women utilizing such services in 2016, but significant growth potential due to demographic trends. The deal, valued at 2 billion yen, aims to capitalize on synergies with MEDIROM’s existing wellness services, expand its healthcare technology portfolio, and enhance its market position.

On June 20, 2024, MEDIROM Healthcare Technologies (NASDAQ: MRM) was one of four Nasdaq-listed Japanese companies participating in the NASDAQ JAPAN IR EVENT 2024 at Nasdaq's U.S. headquarters. The event aimed to elevate the presence of Japanese companies in the U.S. market. Over 120 investors and media attended, providing a platform for in-depth investor-company interactions. Koji Eguchi, CEO of MEDIROM, emphasized the event's success in fostering deeper understanding and communication between investors and Japanese companies.

The four presenting companies were MEDIROM Healthcare Technologies, SYLA Technologies, Earlyworks, and Lead Real Estate. The event is part of an ongoing initiative to regularly hold JAPAN IR events at Nasdaq headquarters to highlight Japanese companies' appeal worldwide.

Medirom Healthcare Technologies (NASDAQ: MRM) announced its financial results for fiscal year 2023, reporting net profit and positive adjusted EBITDA for the second consecutive year. Key contributors were its directly-operated wellness salons, the sale of 30 wellness salons, and growth in its Lav digital wellness app.

Revenues totaled $48.5 million, slightly down by 1.8% from 2022. The Relaxation Salon segment saw a modest revenue increase of 1.5%, but the Digital Preventative Healthcare segment saw a 48.1% decline. Operating expenses rose by 5.3%, leading to an operating loss of $2.8 million. Net income fell 22.8% to $816,000.

Despite the profit, adjusted EBITDA dropped by 19.5% to $2.2 million. Key factors were increased payroll, outsourcing costs, and interest expenses due to convertible bonds. Medirom launched full-scale operations of its REMONY Monitoring System and worked on expanding its B2B sales of healthtech platforms like MOTHER Bracelet and Gateway.

The NASDAQ JAPAN IR EVENT will take place at Nasdaq MarketSite in Times Square on June 20, 2024. MEDIROM Healthcare Technologies will participate, along with four other companies. The event aims to highlight the appeal of Japanese companies to the global market. Since MEDIROM's Nasdaq listing in December 2020, the number of Japanese companies on Nasdaq has grown to eight. The event is free with pre-registration required by June 7. It runs from 3:00pm to 9:00pm and includes presentations and an after-party.

MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announced a stock repurchase plan under which COZY LLC, controlled by CEO Kouji Eguchi, may buy back up to JPY 50 million of the Company’s American Depositary Shares (ADSs). The Board approved the Plan on January 18, 2023, with purchases expected to occur between February 13, 2023 and March 31, 2023. Currently, Mr. Eguchi holds approximately 38.6% of the Company’s common shares, reflecting his confidence in MEDIROM’s fundamentals and growth potential. The stock repurchase will be funded personally by Mr. Eguchi, although there is no obligation for COZY to complete the purchases.

MEDIROM Healthcare Technologies Inc. (MRM) reported total revenue of approximately JPY6.5 billion (about $49.3 million) for the fiscal year ended December 31, 2022. This marks an increase of JPY1.1 billion ($8.3 million) compared to the previous year, fueled by strong contributions from newly acquired subsidiaries and rising sales at company-operated salons post-COVID-19. Operating income improved to JPY240 million ($1.8 million), reversing an operating loss from the prior year. Despite increased operating expenses of approximately JPY6.26 billion ($47.5 million), the company maintained its profitability. Management remains optimistic about continuing growth into 2023.